Achaogen Announces New Employment Inducement Grants
25 janv. 2018 08h00 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen to Present at J.P. Morgan Healthcare Conference
03 janv. 2018 16h01 HE
|
Achaogen, Inc.
– Company presentation scheduled for January 11, 2018 – SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company...
Achaogen Announces Positive Top-Line Results from First Clinical Trial of Orally-Administered Antibacterial Candidate C-Scape
02 janv. 2018 08h01 HE
|
Achaogen, Inc.
-- C-Scape was well tolerated across all doses studied in Phase 1 trial, with no drug-drug interaction between the previously approved compounds when dosed in combination -- -- C-Scape is a...
Achaogen Announces FDA Acceptance of New Drug Application with Priority Review for Plazomicin for Treatment of Complicated Urinary Tract Infections and Bloodstream Infections
02 janv. 2018 08h01 HE
|
Achaogen, Inc.
-- Investigational drug has potential to treat certain MDR gram-negative pathogens, including carbapenem-resistant Enterobacteriaceae (CRE) -- -- FDA sets action date of June 25, 2018 -- SOUTH SAN...
Achaogen Announces New Employment Inducement Grants
22 déc. 2017 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Appoints Blake Wise Chief Executive Officer
11 déc. 2017 16h01 HE
|
Achaogen, Inc.
- Dr. Kenneth Hillan to become President, R&D - - Succession designed to lead Achaogen through next phase of growth as a commercial-stage company - - Transition effective January 1, 2018 - ...
Achaogen to Participate in the Guggenheim Securities 5th Annual Boston Healthcare Conference
30 nov. 2017 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Announces New Employment Inducement Grants
24 nov. 2017 08h01 HE
|
Achaogen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Reports Third Quarter 2017 Financial Results and Provides Corporate Update
08 nov. 2017 16h01 HE
|
Achaogen, Inc.
-- Plazomicin New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) for the treatment of complicated urinary tract infections (cUTI) and bloodstream infections (BSI) -- ...
Achaogen to Present at the Stifel 2017 Healthcare Conference
06 nov. 2017 08h01 HE
|
Achaogen, Inc.
-- Company presentation scheduled for November 14, 2017 at 8:45 a.m. EST -- SOUTH SAN FRANCISCO, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage...